In the TCGA tonsil cancer and TCGA HNSC data, TP53 mutations were the most common (83.3% and 82.2%, respectively), followed by PIK3CA (16.7% and 13.5%, respectively) and CDKN2A (16.7% and 23.6%, respectively) (Figure 4C) mutations, comparable to the findings in our cohort (75.0%, 37.5%, and 25.0%, respectively). Here, TP53 is linked to medical procedure.